Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.77 USD | +8.59% | +21.23% | 0.00% |
May. 15 | Transcript : ICAD, Inc., Q1 2024 Earnings Call, May 15, 2024 | |
May. 15 | Earnings Flash (ICAD) ICAD Posts Q1 Revenue $5M, vs. Street Est of $4.4M | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 62% by 2026.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
0.00% | 42.98M | D+ | ||
+12.50% | 229B | B | ||
+14.52% | 195B | B- | ||
+17.51% | 142B | B- | ||
+28.96% | 109B | A- | ||
+3.27% | 64.85B | A- | ||
+18.16% | 54.33B | B+ | ||
+7.63% | 52.09B | B+ | ||
+10.95% | 45.15B | A | ||
+5.10% | 37.39B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ICAD Stock
- Ratings iCAD, Inc.